Tyrosinase mRNA levels in the blood of uveal melanoma patients: Correlation with the number of circulating tumor cells and tumor progression

Melanoma Research

Volumn 20, Issue 4, 2010, Pages 303-310

  Pinzani, Pamela ^a   Mazzini, Cinzia ^a   Salvianti, Francesca ^a   Massi, Daniela ^a   Grifoni, Raffaella ^a   Paoletti, Costanza ^a   Ucci, Francesca ^a   Molinara, Elena ^a   Orlando, Claudio ^a   Pazzagli, Mario ^a   Neri, Bruno ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

circulating tumor cells; real time RT PCR; tyrosinase expression; uveal melanoma

Indexed keywords

MONOPHENOL MONOOXYGENASE; MESSENGER RNA;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; GENE EXPRESSION; HUMAN; MALE; METASTASIS; OVERALL SURVIVAL; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL; TUMOR GROWTH; TUMOR RECURRENCE; TUMOR VOLUME; UVEA MELANOMA; BLOOD; DISEASE COURSE; GENETICS; LONGITUDINAL STUDY; MELANOMA; MIDDLE AGED; PATHOLOGY; TUMOR CELL LINE; TUMOR EMBOLISM; UVEA TUMOR; VERY ELDERLY;

AGED; AGED, 80 AND OVER; CELL LINE, TUMOR; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION; HUMANS; LONGITUDINAL STUDIES; MALE; MELANOMA; MIDDLE AGED; MONOPHENOL MONOOXYGENASE; NEOPLASTIC CELLS, CIRCULATING; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; UVEAL NEOPLASMS;

EID: 77955700927     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/CMR.0b013e32833906e3     Document Type: Article

References (32)

1. Cutler SJ, Young JL. Third national cancer survey: incidence data. NCI Monogr 1975; 41:1.
2. Vidal JL, Bacin F, Albuisson E, Rozan R, Desjardins L, D'Hermies F, et al. ''Melanoma 92''. Epidemiological study of uveal melanoma in France. J Fr Ophtalmol 1995; 18:520-528.
3. Margo CE, Mulla Z, Billiris K. Incidence of surgically treated uveal melanoma by race and ethnicity. Ophthalmology 1998; 105:1087-1090.
4. Gass JD, Gieser RG, Wilkinson CP, Beahm DE, Pautler SE. Bilateral diffuse uveal melanocytic proliferation in patients with occult carcinoma. Arch Ophthalmol 1990; 108:527-533.
5. Callejo SA, Antecka E, Blanco PL, Edelstein C, Burnier MN Jr. Identification of circulating malignant cells and its correlation with prognostic factors and treatment in uveal melanoma. A prospective longitudinal study. Eye 2007; 21:752-759.
6. Schuster R, Bechrakis NE, Stroux A, Busse A, Schmittel A, Scheibenbogen C, et al. Circulating tumor cells as prognostic factor for distant metastases and survival in patients with primary uveal melanoma. Clin Cancer Res 2007; 13:1171-1178.
7. Pantel K, Cote RJ, Fodstad Ø. Detection and clinical importance of micrometastatic disease. J Natl Cancer Inst 1999; 91:1113-1124.
8. Sidransky D. Nucleic acid-based methods for the detection of cancer. Science 1997; 278:1054-1058.
9. Koyanagi K, Mori T, O'Day SJ, Martinez SR, Wang H-J, Hoon DSB. Association of circulating tumor cells with serum tumor-related methylated dna in peripheral blood of melanoma patients. Cancer Res 2006; 66:6111-6117.
10. Arenberger P, Arenbergerova M, Vohradnikova O, Kremen J. Early detection of melanoma progression by quantitative real-time RT-PCR analysis for multiple melanoma markers. Keio J Med 2008; 57:57-64.
11. Xi L, Nicastri DG, El-Hefnawy T, Hughes SJ, Luketich JD, Godfrey TE. Optimal markers for real-time quantitative reverse transcription PCR detection of circulating tumor cells from melanoma, breast, colon, esophageal, head and neck, and lung cancers. Clin Chem 2007; 53:1206-1215.
12. Arenberger P, Arenbergerova M, Gkalpakiotis S, Lippert J, Stribrna J, Kremen J. Multimarker real-time reverse transcription-PCR for quantitative detection of melanoma-associated antigens: a novel possible staging method. J Eur Acad Dermatol Venereol 2008; 22:56-64.
13. Medic S, Pearce RL, Heenan PJ, Ziman M. Molecular markers of circulating melanoma cells. Pigment Cell Res 2007; 20:80-91.
14. Koyanagi K, Kuo C, Nakagawa T, Mori T, Ueno H, Lorico AR Jr, et al. Multimarker quantitative real-time PCR detection of circulating melanoma cells in peripheral blood: relation to disease stage in melanoma patients. Clin Chem 2005; 51:981-988.
15. Keilholz U, Goldin-Lang P, Bechrakis NE, Max N, Letsch A, Schmittel A, et al. Quantitative detection of circulating tumor cells in cutaneous and ocular melanoma and quality assessment by real-time reverse transcriptase-polymerase chain reaction. Clin Cancer Res 2004; 10:1605-1612.
16. Mellado B, Del Carmen Vela M, Colomer D, Gutierrez L, Castel T, Quintó L, et al. Tyrosinase mRNA in blood of patients with melanoma treated with adjuvant interferon. J Clin Oncol 2002; 20:4032-4039.
17. Mocellin S, Keilholz U, Rossi CR, Nitti D. Circulating tumor cells: the 'leukemic phase' of solid cancers. Trends Mol Med 2006; 12:130-139.
18. Foss AJ, Guille MJ, Occleston NL, Hykin PG, Hungerford JL, Lightman S. The detection of melanoma cells in peripheral blood by reverse transcription polymerase chain reaction. Br J Cancer 1995; 72:155-159.
19. Borovanska J, Krasny J, Stribrna J, Pohlreich P, Kremen J, Sach J. Detection of tumor circulating cells in patients with ocular melanoma. Cesk Slov Oftalmol 2002; 58:238-246.
20. Collaborative Ocular Melanoma Study Group. Histopathologic characteristic of uveal melanomas in eyes enucleated: COMS Report No. 6. Am J Ophthalmol 1998; 125:745-766.
21. Vona G, Sabile A, Louha M, Sitruk V, Romana S, Schutze K, et al. Isolation by size of epithelial tumor cells: a new method for the immunomorphological and molecular characterization of circulating tumor cells. Am J Pathol 2000; 156:57-63.
22. Diener-West M, Reynolds SM, Agugliaro DJ, Caldwell R, Cumming K, Earle JD, et al. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma, II: characteristics of patients enrolled and not enrolled. Collaborative Ocular Melanoma Study Group. Report No. 17. Arch Ophthalmol 2001; 119:951-965.
23. Rainen L, Oelmueller U, Jurgensen S, Wyrich R, Ballas C, Schram J, et al. Stabilization of mRNA expression in whole blood samples. Clin Chem 2002; 48:1883-1890.
24. Schroeder A, Mueller O, Stocker S, Salowsky R, Leiber M, Gassmann M, et al. The RIN: an RNA integrity number for assigning integrity values to RNA measurements. BMC Mol Biol 2006; 7:3-16.
25. Fleige S, Walf V, Huch S, Prgomet C, Sehm J, Pfaffl MW. Comparison of relative mRNA quantification models and the impact of RNA integrity in quantitative real-time RT-PCR. Biotechnol Lett 2006; 28:1601-1613.
26. Paterlini-Brechot P, Benali NL. Circulating tumor cells (CTC) detection: clinical impact and future directions. Cancer Lett 2007; 253:180-204.
27. Fernandes BF, Belfort RN, Di Cesare S, Burnier MN Jr. Circulating uveal melanoma cells: should we test for them? Can J Ophthalmol 2008; 43:155-158.
28. Tobal K, Sherman LS, Foss AJ, Lightman SL. Detection of melanocytes from uveal melanoma in peripheral blood using the polymerase chain reaction. Invest Ophthalmol Vis Sci 1993; 34:2622-2625.
29. Mitropapas G, Nezos A, Halapas A, Pissimissis N, Lembessis P, Sourla A, et al. Molecular detection of tyrosinase transcripts in peripheral blood from patients with malignant melanoma: correlation of PCR sensitivity threshold with clinical and pathologic disease characteristics. Clin Chem Lab Med 2006; 44:1403-1409.
30. Stathopoulou A, Gizi A, Perraki M, Apostolaki S, Malamos N, Mavroudis D, et al. Real-time quantification of CK-19 mRNA-positive cells in peripheral blood of breast cancer patients using the lightcycler system. Clin Cancer Res 2003; 9:5145-5151. (Pubitemid 37413564)
31. Gradilone A, Gazzaniga P, Silvestri I, Gandini O, Trasatti L, Lauro S, et al. Detection of CK19, CK20 and EGFR mRNAs in peripheral blood of carcinoma patients: correlation with clinical stage of disease. Oncol Rep 2003; 10:217-222.
32. Harbour JW. Molecular prognostic testing and individualized patient care in uveal melanoma. Am J Ophthalmol 2009; 148:823-829.